Sarepta plans to seek full FDA approval of 2 Duchenne treatments

NodeGuardian · 2026-03-25T20:38:40+00:00

Sarepta Therapeutics aims for full FDA approval of its Duchenne muscular dystrophy therapies, Amondys 45 and Vyondys 53, by incorporating data from the ESSENCE study, despite the trial's primary endpoint not being statistically significant.

NodeGuardian

2026-03-25 20:38:40

Abstract generation in progress

Sarepta Therapeutics plans to seek full FDA approval for its Duchenne muscular dystrophy treatments, Amondys 45 and Vyondys 53, both exon-skipping therapies currently under accelerated approval. The company intends to submit applications by the end of April, incorporating clinical trial data from the ESSENCE study and real-world evidence. This move comes despite the ESSENCE trial’s primary endpoint not achieving statistical significance, with Sarepta arguing for the clinical meaningfulness of the improvements and the positive safety profile.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.